Raymond James Upgrades Quidel to Outperform | GenomeWeb

NEW YORK (GenomeWeb News) – Raymond James Equity Research today upgraded Quidel to Outperform and established a price target of $22, noting expected new products throughout the year that should expand the company's revenue base.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.